Shenzhen Salubris Pharmaceuticals (002294.SZ): SAL0137 Receives Clinical Trial Approval

BRIEF-Shenzhen Salubris Pharmaceuticals Plans To Seek Hong Kong Listing

Shenzhen Salubris Pharmaceuticals Says Co Plans to Seek Hong Kong Listing

Salubris Pharmaceuticals' Three Drugs Placed in China's Medical Insurance Catalog

Salubris Pharmaceuticals Gets Nod to Trial Hyperaldosteronism Drug

Shenzhen Salubris Pharmaceuticals (002294.SZ): XinChaoTuo, FuLiAn, and EnNaLuo Included in National Reimbursement Drug List

Shenzhen Salubris Pharmaceuticals Gets China Approval for Chronic Kidney Disease Tablet Clinical Trials

Shenzhen Salubris Pharmaceuticals (002294.SZ): Innovative Small-Molecule Drug SAL0139 Approved for Clinical Trials in Hyperlipidemia Treatment

Salubris Pharmaceuticals Q3 Profit Up 31%, Revenue Rises 16%

Shenzhen Salubris Pharmaceuticals Gets Acceptance of Clinical Trial Application for Elevated Lipoprotein Drug

Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) Receives Acceptance for Clinical Trial Application of SAL0137

Shenzhen Salubris Pharmaceuticals Gets Regulatory Acceptance for Clinical Trial Application

Shenzhen Salubris Pharmaceuticals (002294.SZ): Clinical Trial Application for SAL0140 Drug Receives Regulatory Acceptance

Salubris Pharmaceuticals Gets China Marketing Approval for High Cholesterol Injection

Shenzhen Salubris Pharmaceuticals (002294.SZ): Clinical Trial Application for SAL0139 Drug Approved for Review

Shenzhen Salubris Pharmaceuticals (002294.SZ): Clinical Trial Application for Self-Developed Innovative Small Molecule Drug SAL0140 Tablet Receives Acceptance

Shenzhen Salubris Pharmaceuticals' Attributable Profit Jumps 6% in H1

Shenzhen Salubris Pharmaceuticals Releases Half-Year Report with Net Profit Up 6.1% in First Half

Shenzhen Salubris Pharmaceuticals Reports First Half Results with Net Profit of 365 Million Yuan, Up 6.10%